Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Defence’s Succesfull Accutoxtm Pre-Clinical Efficacy Study Complete Ready for Phase I IND Filing
Details : AccuTOX with anti-PD-1 and anti-LAG3 has shown to be very efficient at impeding tumor growth in many animal models including T-cell lymphoma, breast cancer and melanoma.
Product Name : AccuTOX
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : AccuTOX,Nivolumab,Relatlimab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable